A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5mcg (Delivered by the Respimat Inhaler) and Tiotropium 18mcg (Delivered by the HandiHaler) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat Inhaler) and Tiotropium 18mcg (Delivered by the HandiHaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Trial Profile

A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5mcg (Delivered by the Respimat Inhaler) and Tiotropium 18mcg (Delivered by the HandiHaler) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat Inhaler) and Tiotropium 18mcg (Delivered by the HandiHaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Completed
Phase of Trial: Phase III

Latest Information Update: 20 May 2015

At a glance

  • Drugs Olodaterol (Primary) ; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms ANHELTO 1
  • Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 May 2013 Planned number of patients changed from 1120 to 1134 as reported by ClinicalTrials.gov.
    • 15 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top